399 — Innovative Pharmaceutical Biotech Balance Sheet
0.000.00%
Last trade - 00:00- HK$318.89m
- HK$2.14bn
- HK$6.59m
Annual balance sheet for Innovative Pharmaceutical Biotech, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 22.9 | 8.99 | 4.08 | 1.33 | 3.08 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 15.6 | 15.3 | 9.5 | 6.41 | 5.12 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 42.2 | 28.8 | 18.9 | 9.88 | 9.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.47 | 1.19 | 2.82 | 0.941 | 0 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 1,419 | 1,403 | 1,395 | 1,384 | 1,383 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 70.5 | 801 | 99.8 | 1,147 | 392 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,809 | 1,999 | 1,944 | 2,179 | 1,995 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -390 | -595 | -549 | -795 | -612 |
| Total Liabilities & Shareholders' Equity | 1,419 | 1,403 | 1,395 | 1,384 | 1,383 |
| Total Common Shares Outstanding |